Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Johnson & Johnson President Brings Extensive McNeil Background To Post

This article was originally published in The Tan Sheet

Executive Summary

Johnson & Johnson's appointment of James Lenehan, 53, as president signals a strong commitment by the company to its consumer products segments, despite the firm's shift in emphasis toward its pharmaceutical business over the past ten years
Advertisement

Related Content

J&J asks MHRA for antifungal switch
J&J asks MHRA for antifungal switch
J&J asks MHRA for antifungal switch
J&J’s Lenehan Steps Down; Company Vision “Pretty Well Set”
J&J’s Lenehan Steps Down; Company Vision “Pretty Well Set”
J&J’s Lenehan Steps Down; Company Vision “Pretty Well Set”
McNeil Supplements Nutritionals Portfolio With Viactiv
Monistat 1 OTC Switch May Help J&J Gain Feminine Category Lead
J&J Nizoral AD 1% ketoconazole dandruff shampoo approved for OTC use Oct. 10.
J&J Nizoral AD 1% ketoconazole dandruff shampoo approved for OTC use Oct. 10.

Topics

Advertisement
UsernamePublicRestriction

Register

PS093545

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel